Ampio Pharmaceuticals, Inc. (NY:AMPE)

N/A UNCHANGED

Last Price Updated: 8:00 PM EDT, Apr 12, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ampio Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For March 29, 2022 ↗

March 29, 2022

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.

Via Benzinga

Earnings Scheduled For May 5, 2021 ↗

May 05, 2021

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...

Via Benzinga

Earnings Preview For Ampio Pharmaceuticals ↗

March 28, 2022

Ampio Pharmaceuticals (AMEX:AMPE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Ampio...

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022 ↗

March 24, 2022

Upgrades For iRobot Corp (NASDAQ:IRBT), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, iRobot showed an EPS of $1....

Via Benzinga

63 Biggest Movers From Yesterday ↗

March 25, 2022

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet...

Via Benzinga

Why Ampio Pharmaceuticals Stock Is Rising Today ↗

March 24, 2022

Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated...

Via Benzinga

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

26 Stocks Moving in Thursday's Pre-Market Session ↗

March 03, 2022

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) rose 35% to $1.06 in pre-market trading. Kiromic BioPharma, last month, reported changes in management and board of...

Via Benzinga

Ampio Highlights Promising Ampion Data In Knee Osteoarthritis ↗

March 03, 2022

Ampio Pharmaceuticals Inc (NYSE: AMPE) announced data from the modified Intent-to-Treat (mITT) population in the AP-013 Phase 3 trial of Ampion in severe osteoarthritis of...

Via Benzinga

Ampio To Test Inhaled COVID-19 Treatment In India ↗

September 21, 2021

The Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has approved Phase 2 COVID-19 trial of Ampio...

Via Benzinga

Why Ampio Pharmaceuticals Stock Is Trading Higher Today ↗

September 15, 2021

Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in...

Via Benzinga

EXCLUSIVE: Ampio's Ampion Shows Benefit In Late-Stage Knee Osteoarthritis Study ↗

September 15, 2021

Ampio Pharmaceuticals Inc (NYSE: AMPE) has reported top-line results from the AP-013 Phase 3 trial evaluating the Company's intra-articular (IA) injection of Ampion in...

Via Benzinga

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

Here's Why Ampio Pharmaceuticals Stock Is Surging Today ↗

August 05, 2021

A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.

Via The Motley Fool

Ampio To Present At October Scientific Conference Evidence Of Ampion's Role In Treating Lupus Nephritis, COVID-19 ↗

July 28, 2021

Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharma developing immunotherapies for inflammatory conditions, is set to present data on lead drug Ampio at a scientific conference...

Via Benzinga

Ampio's Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway ↗

June 25, 2021

Ampio Pharmaceuticals, Inc. (NYSE: AMPE) announced an update to its COVID-19 program that is evaluating its lead asset Ampion. What Happened: Colorado-based Ampio announced the...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗

June 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion ↗

June 15, 2021

Ampio Pharmaceuticals Inc (NYSE: AMPE) has received regulatory approval to expand enrollment of its AP-019 Phase 2 study to India, assessing inhaled Ampion to...

Via Benzinga

EXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 Symptoms ↗

May 10, 2021

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharma developing immunology-based therapies for inflammatory diseases, announced Monday it has received approval to initiate a...

Via Benzinga

Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality ↗

April 27, 2021

Ampio Pharmaceuticals Inc (NYSE: AMPE) revealed positive results from its AP-014 Phase 1 trial utilizing inhaled Ampion in treating respiratory distress in...

Via Benzinga

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.